3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Advanced Cancer
6
Melanoma
3
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Malignancies Multiple
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Endometrial Adenocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Advanced Gastric Cancer
1
Interventions
Paclitaxel
9
apatinib
8
Capecitabine
7
Oxaliplatin
6
Cisplatin
5
camrelizumab
4
S 1 (combination)
4
Fluorouracil
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
titanium silicide
2
Leucovorin
2
vorolanib
1
trifluridine tipiracil drug combination
1
tipiracil
1
spartalizumab
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
lobaplatin
1
linrodostat
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
Trifluridine
1
Sunitinib
1
SHR-1701
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Gastric Cancer
×
linrodostat
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts